Research
Hormonal
GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide can achieve weight loss comparable to sleeve gastrectomy in selected patients, but are limited by real-world factors like cost, tolerability, and adherence.
GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, often achieving 15-20% body weight reduction. However, success depends on continuous use; stopping the medication often leads to weight regain. Managing side effects through gradual dosing and addressing cost/access are key to long-term success.
GoodQualifiesHIGH confidence
These newer therapies capable of eliciting weight loss of 20% or greater in some patients... The real-world effectiveness of GLP1RA is hindered by issues including cost and tolerability.
Why this rating
Supported by multiple Phase 3 RCTs (STEP, SURMOUNT) and observational data.
Source
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Mathula Muhundan et al. · Advances in Therapy · 2026
DOI 10.1007/s12325-026-03494-7
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery remains the most efficacious treatment for obesity, producing sustained weight loss of approximately 20% or higher and superior metabolic improvements compared to pharmacotherapy alone.Good
- Using GLP-1 RAs post-bariatric surgery can enhance weight loss outcomes and prevent weight regain, whereas using them pre-surgery (neoadjuvant) does not improve surgical outcomes and may slightly reduce weight loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →